Payment overview · 2025
General Payments
$745.67
32 reported records · 15 companies
Healthcare provider profile · identity verified
William Pollock, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CORONA, CA · NPI 1881867919
Verified facts
What the public records show
CMS Open Payments records show William Pollock, PA-C received $745.67 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.55 | 25.6% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.13 | 12.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.91 | 9.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.82 | 7.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.25 | 7.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.24 | 7.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.70 | 5.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.66 | 4.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $31.99 | 4.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.65 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.33 | 3.1% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $23.31 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.19 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.32 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.62 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.67 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $136.91 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.33 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.13 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.91 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.91 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $69.39 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.25 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.25 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.24 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.66 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.40 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 92 |
| Lisinopril | Lisinopril | 257 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 51 |
| Gabapentin | Gabapentin | 170 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 43 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 38 |
| Omeprazole | Omeprazole | 118 | 36 |
| Alprazolam | Alprazolam | 115 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 17 |
| Losartan Potassium | Losartan Potassium | 102 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 27 |
| Lorazepam | Lorazepam | 88 | 13 |
| Furosemide | Furosemide | 87 | 24 |
| Famotidine | Famotidine | 83 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 29 |
| Trazodone Hcl | Trazodone Hcl | 73 | 21 |
| Eliquis | Apixaban | 68 | 20 |
| Montelukast Sodium | Montelukast Sodium | 67 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 21 |
| Atenolol | Atenolol | 65 | 17 |
| Jardiance | Empagliflozin | 64 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 22 |
| Simvastatin | Simvastatin | 55 | 15 |
| Glipizide Er | Glipizide | 54 | 17 |
| Meloxicam | Meloxicam | 51 | 13 |
| Valsartan | Valsartan | 50 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 23 |
| Azithromycin | Azithromycin | 45 | 39 |
| Tramadol Hcl | Tramadol Hcl | 45 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 29 |
| Finasteride | Finasteride | 43 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 27 |
| Glipizide | Glipizide | 35 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Allopurinol | Allopurinol | 28 | 11 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 13 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Ketoconazole | Ketoconazole | 16 | 14 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.67 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, GEMTESA, GIMOTI, IBSRELA, JARDIANCE, Kerendia, Leqembi, MOUNJARO, MYFEMBREE, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TONMYA, UBRELVY, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error